S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma. (Q44664669)
Jump to navigation
Jump to search
scientific article published on 28 May 2013
Language | Label | Description | Also known as |
---|---|---|---|
English | S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma. |
scientific article published on 28 May 2013 |
Statements
S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma (English)
Raphael Maréchal
Pieter Demetter
Franck Bonnetain
Christophe Louvet
François Paye
Jean-Christophe Vaillant
Jean Closset
Isabelle Salmon
Jean-François Emile
Jean-Luc Van Laethem
Magali Svrcek
Armelle Bardier-Dupas